Study has been concluded
Creighton University’s Lynch Cancer Research Center (Formerly known as the Hereditary Cancer Center) received a three-year, $731,278 grant from the U.S. Department of Defense to study the role heredity plays in prostate cancer among African Americans.
“Prostate cancer is the leading cause of cancer death among men in the United States. African American men have two times the occurrence of prostate cancer as do Caucasian men and suffer a significantly higher mortality as well,” said Henry Lynch, MD, principal investigator and Creighton Hereditary Cancer Center director.
While it’s estimated that about 10 percent of all prostate cancers have a hereditary link, the problem has been understudied in African Americans. With few exceptions, relatively little is known about the role genetics play in this population, noted Lynch, holder of the Charles F. and Mary C. Heider Endowed Chair in Cancer Research.
“The study will focus on identifying the hereditary factors of the disease that are specific to African Americans. The goal is to develop early and intensive screening and prevention management strategies that will decrease African Americans’ incidence of as well as death rate from hereditary prostate cancer,” Lynch said.
Jackson State University in Mississippi is collaborating in the study. The goal is to involve 300 African American prostate cancer patients from the Omaha area and about 500 from Jackson, Miss., in the effort.
The research team includes members of Creighton’s Hereditary Cancer Center; Olúgbémiga Ekúndayò, M.D., associate professor of epidemiology at Jackson State University, and his staff; Sade Kosoko-Lasaki, M.D., associate vice president of Health Sciences Multicultural and Community Affairs at Creighton and co-director of the University’s Center for Promoting Health and Health Equality; and Paulos Yohannes, M.D., Creighton assistant clinical professor of surgery.
To learn more about the work of Creighton’s Hereditary Cancer Center, visit Hereditary Cancer Center.
Annals of Internal Medicine: What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation